Pharmacopoeial

ICH HARMONISED TRIPARTITE GUIDELINE

pharmacopoeial text that has been submitted to the Q4B evaluation process. Any change to pharmacopoeial text that has been proposed to, or recommended through, the Q4B evaluation process will prompt a Q4B EWG review to assess both the merit of the change and the appropriateness of any subsequent Q4B activity related to that text. 2. GUIDELINES

  Pharmacopoeial

3.4 TEST FOR BACTERIAL ENDOTOXINS Final text for …

editorial modifications, is one that has undergone pharmacopoeial harmonization by the Pharmacopoeial Discussion Group (PDG) of the European Pharmacopoeia (Ph.Eur), Japanese Pharmacopoeia (JP) and United States Pharmacopeia (USP). 3.4 – …

  Bacterial, Tests, Texts, Final, Endotoxins, Pharmacopoeial, Test for bacterial endotoxins final text for

Stability Existing Corrected March 2007

pharmacopoeial monograph has been demonstrated for the particular named source (refer to the Note for Guidance on Summary of Requirements for Active Substances in Part II of the Dossier (CPMP/QWP/297/97)); b) The applicant should fix a re-test period based on the results of long term testing, taking the results of testing under accelerated or ...

  Pharmacopoeial

European Medicines Agency

Inorganic impurities are normally detected and quantified using pharmacopoeial or other appropriate procedures. Carry-over of catalysts to the new drug substance should be evaluated during development. The need for inclusion or exclusion of inorganic impurities in the new drug substance specification should be discussed.

  Pharmacopoeial

ICH HARMONISED TRIPARTITE GUIDELINE

Q6B Document History First Codification History Date New Codification November 2005 Q6B Approval by the Steering Committee under Step 2 and release for public consultation.